Oncotarget · 2017 · 66 citations · 26 references
MedicineOncologySurgeryHematologic OncologyOncologic SurgeryThoracic OncologyLung CancerPlatelet FunctionPlatelet PhysiologyPlatelet TransfusionPreoperative Oncology AssessmentThoracic SurgeryClinical Laboratory EvaluationLaboratory Test EvaluationNon-small Cell Lung Cancer TherapyPlatelet Count MonitoringPlatelet Transfusion ThresholdsPrognostic BiomarkersPulmonary Preoperative AssessmentUnivariate Analysis
// Liuwei Gao 1, 2, 3 , Hua Zhang 1, 2, 3 , Bin Zhang 1, 2, 3 , Lianmin Zhang 1, 2, 3 , Changli Wang 1, 2, 3 1 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China 2 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China 3 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Lung Cancer Center, Tianjin, China Correspondence to: Changli Wang, email: changliwang1088@yeah.net Keywords: combination of platelet count and mean platelet volume, non-small cell lung cancer, thrombocytosis, mean platelet volume, prognosis Received: September 20, 2016 Accepted: December 13, 2016 Published: January 31, 2017 ABSTRACT The aim of the present study was to investigate the prognostic value of the combination of preoperative platelet count (PLT) and mean platelet volume (MPV) in patients with primary operable non-small cell lung cancer (NSCLC). We retrospectively analysed data from 546 patients with NSCLC who underwent complete resection at our institution from 2006 to 2010. Patients’ clinical characteristics and laboratory test data at initial diagnosis were collected. Both preoperative PLT and MPV (COP-MPV) were calculated on the basis of the data obtained using the recommended cut-off values of 300 × 10 9 L −1 and 11.0 fL, respectively. Patients with both an elevated PLT (≥300× 10 9 L −1 ) and a decreased MPV (<11.0 fL) were assigned a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively. Multivariate analysis of the 9 clinical laboratory variables selected by univariate analysis revealed that preoperative COP-MPV was a significantly independent prognostic factor for overall survival (OS) (hazard ratio, 1.775; 95% confidence interval, 1.500–2.101; P < 0.001) and disease-free survival (DFS) (hazard ratio, 1.719; 95% confidence interval, 1.454–2.033; P < 0.001). In subgroup analyses for tumour pathological stage (I/II/IIIA) patients, we found that the level of COP-MPV was significantly associated with OS and DFS in each subgroup ( P < 0.001, P < 0.001, P <0.001 for OS and P <0.001, P < 0.001, P =0.001 for DFS, respectively). In conclusion, the preoperative COP-MPV is a promising predictor of postoperative survival in patients with NSCLC and could classify these patients into three independent groups before surgery.
26
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2009 · 9.7K citations · Full text
Philip M. Bath, R J Butterworth · Blood Coagulation & Fibrinolysis · 1996 · 767 citations
Medicine, Cardiology, Hematology +13
The pathophysiology and clinical relevance of platelet heterogeneity
Thompson Cb, J.A. Jakubowski · Blood · 1988 · 202 citations · Full text
Medicine, Hematology, Pathology +14